Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120 by unknown
BriefDefinitive Report
HUMAN EOSINOPHILS EXPRESS CD4 PROTEIN AND BIND
HUMAN IMMUNODEFICIENCY VIRUS 1 gp120
BY DANIEL R. LUCEY, DAVID I. DORSKY, ANNE NICHOLSON-WELLER, AND
PETER F. WELLER
From the Department of Medicine, Harvard Medical School, and the Infectious Diseases Division,
Harvard Thorndike Laboratories, Charles A. Dana Research Institute,
Beth Israel Hospital, Boston, Massachusetts 02215
The CD4 molecule, an N55-kD glycoprotein initially detected with specific mAbs
on the surface of a helper/inducer subset ofhuman T lymphocytes (1, 2), is encoded
by a single gene and is of invariant structure (3, 4). The function of CD4 on T cells
is not completely understood; CD4 can mediate interactions of T cells with cells
bearing class II MHC proteins (4, 5) and can function as a signal-transducing pro-
tein that modulates T cell activation (6, 7). CD4 binds the gp120 protein of HIV1,
and serves as a cellular receptor for HIV-1 (8) and HIV-2 (9). In addition to its ex-
pression on subsets of T lymphocytes, CD4 is expressed on monocytes and cells of
monocyte/macrophage lineage, on which CD4 also functions as a receptor for HIV
(2, 10, 11).
Eosinophils and neutrophils are distinct classes of bone marrow-derived granulo-
cytic leukocytes; in contrast to neutrophils, eosinophils are longer lived and are pre-
dominantly tissue-dwelling cells (12). Eosinophils localize primarily to tissues that
interface with the external environment, including the respiratory, gastrointestinal,
and genitourinary tracts (12). Numbers ofeosinophils increase in the blood and tissues
in association with certain disease processes, and eosinophils are prominent in im-
munologic responses during allergic (13) and helminthic parasitic diseases (14, 15).
In this report we demonstrate that human eosinophils express CD4.
Materials and Methods
Eosinophil Isolation and Culture.
￿
Eosinophils were obtained with informed consent from
five eosinophilic (the hypereosinophilic syndrome, donors 1 and 2; Loa loa filariasis, donors
3 and 4; asymptomatic infection with HIV, donor 5) and four normal donors. For donor
1 eosinophils from leukapheresis were enriched by sedimentation over Hypaque-Ficoll (Phar-
macia Fine Chemicals, Piscataway, NJ); eosinophils from other donors were purified by Per-
coll (Pharmacia Fine Chemicals)density gradient centrifugation (16) to the percentages indi-
cated, as assessed by staining with fast green/neutral red and phloxine/methylene blue (13).
Contaminating cells before culture (day 0) were neutrophils. 1.5 x 106 cells were cultured
in 3 ml RPMI 1640, 10% FCS, and 50 pM recombinant human granulocyte/macrophage
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CSF (rhGM-CSF) (Genzyme, Boston, MA) on a monolayer of Swiss 3T3 fibroblasts, as de-
scribed (17). 1.5 ml of fresh RPMI/rhGM-CSF were exchanged on days 2, 5, and 7 . CD4
expression on 104 cells was measured by flow cytometry (FACScan; Becton Dickinson & Co.,
Mountain View, CA) with fluoresceinated anti-Leu-3a and -b (Becton Dickinson & Co.) and
is expressed relative to a subclass control mAb. Eosinophil granule staining and nuclear mor-
phology were evaluated by staining with fast green/neutral red and phloxine/methylene blue
(13). The absence of both lymphocytes and monocytes was confirmed by finding no more
than background cellular staining by flow cytometric analyses with two fluoresceinated mAbs
(anti-Leu-1, for CD5 on T cells and anti-Leu-M3 for monocytes/macrophages; both from
Becton Dickinson & Co.).
Biosynthetic Labeling of Eosinophil CD4.
￿
Eosinophils (8.7 x 10', >99% eosinophils, 97%
CD4') from a hypereosinophilic donor were harvested after 15 d of culture with rhGM-CSF
and 3T3 fibroblasts, as described above. After washing in PBS eosinophils were resuspended
in 1 ml HBSS and pulse labeled for 1 h with 700 gCi "S-methionine (Tran"S-label; ICN
Radiochemicals, Costa Mesa, CA) at 37°C, 5% C02 . Eosinophils were lysed in RIPA buffer
(50 mM Tris, pH 8.0, 150 mM NaCl, 1 % sodium deoxycholate, 1 % Triton X-100, 0.1 % SDS)
for 10 min at 4°C . After centrifugation (16,000 g, 15 min, 4°C), the soluble extract was im-
munoabsorbed in parallel with 0.6 gg control antibody (UPC 10; Cappel Laboratories, Mal-
vern, PA) or 0.5 pg anti-OKT4 or anti-OKT4A (both from Ortho Diagnostic Systems, Inc.,
Westwood, MA). After 2 h at 4°C, 50 pl protein A-Sepharose (Genzyme) was added for 45
min. Protein A-Sepharose complexes were washed three times with RIPA buffer and once
with water and then boiled for 3 min in Laemmli sample buffer (18). Proteins were resolved
on SDS-PAGE gels (1°jo SDS, 10 ° Jo polyacrylamide) and visualized by fluorography of gels
for 3 d at -70°C with Kodak X-GMAT film.
HIV-1 GP120 Binding.
￿
Cells from donor 1 were maintained in culture for 10 d with 50
pM rhGM-CSF/3T3 fibroblasts, as described above, and then collected (>99% eosinophils,
>99% viable). 1.5 x 10' eosinophils in 1 ml of Ca", Mgt'-free HBSS were incubated at
37°C for 30 min with or without 10 gg of partially purified HIV-1 gp120, which had been
immunoaffinity purified from culture fluids of HTLVIIIB-infected H9 cells. Eosinophils were
pelleted, resuspended, and stained for 30 min at 4°C with 10 pl of anti-OKT4, anti-OKT4A
(both from Ortho Diagnostic Systems, Inc.) or control UPC-10 (Cappel Laboratories) mAb.
After two washes in HBSS with 0.1% BSA, cells were stained at 4°C for 30 min with fluorescei-
nated goat anti-mouse Ig (Becton Dickinson & Co.), washed twice with HBSS/0.1% BSA,
fixed with 1% paraformaldehyde, and analyzed by flow cytometry.
Results and Discussion
Eosinophils were isolated from the blood of nine donors (Table 1). After depletion
of mononuclear leukocytes and further purification, eosinophil-enriched leukocytes
were incubated with fluoresceinated mAbs anti-Leu-3a and -b, which recognize epi-
topes on CD4. By flow cytometry CD4 expression was demonstrable on the eosinophil-
enriched cells (Table I, Fig. 1). Eosinophils derived from the blood of all donors,
both normal and those with heightened eosinophilia due to parasitic infections and
idiopathic diseases, expressed CD4. Greater percentages of eosinophils from eo-
sinophilic donors, in comparison with normal donors, were CD4+ . Cytochemical
staining demonstrated neutrophils to be the sole contaminant of the eosinophil-
enriched granulocytes, and flow cytometric analyses with fluoresceinated anti-T cell
and anti-monocyte/macrophage mAbs confirmed the absence of lymphocytes and
monocytes.
The eosinophil-enriched cells were placed in culture with rhGM-CSF on monolayers
of 3T3 fibroblasts, and residual contaminating neutrophils died in the early days
ofculture, as previously reported (17) . By day 5 of culture >99 ,70 of all cells, except
the fibroblasts, were eosinophils, and these eosinophils from all donors expressedLUCEY ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
329
TABLE I
Blood Eosinophilia of Donors and CD4 Expression of Eosinophils Before and During Culture
Eosinophils from five eosinophilic and four normal donors were isolated and enriched to the
percentages indicated before culture on day 0. Eosinophils were maintained in culture with
rhGM-CSF and 3T3 fibroblasts, as described in Materials and Methods. CD4 expression
on 104 cells was measured by flow cytometry and is expressed relative to a subclass control
mAb.
* Day of culture.
CD4 (Table I, Fig. 1). The lack of other contaminating leukocytes during culture
was established by cytochemical staining and again by an absence of staining with
the fluoresceinated anti-T cell and anti-monocyte/macrophage mAbs. Cultured eo-
sinophils were pulse labeled with 35S-methionine, and detergent extracts of these
cells were immunoprecipitated with anti-OKT4 and anti-OKT4A, which react with
different epitopes on CD4 (19, 20). Both mAbs precipitated a 35S-labeled 55-kD
polypeptide (Fig. 2). In separate immunoprecipitation studieswith anti-OKT4, the
DAY 0
￿
DAY 5
FIGURE 1.
￿
Flow cytometric analysis ofCD4 ex-
pression on eosinophils. Eosinophil-enriched leu-
kocytes were obtained and analyzed on day 0 be-
fore culture (left panels) and after 5 d in culture
with rhGM-CSF/3T3 fibroblasts (rightpanels). The
top panels are from cells from donor lb and the
bottom panels from donor 4b. Flow cytometry
of 104 cells was performed after cells were stained
with either anti-CD4 mAbs (anti-Leu-3a and -b)
(solid lines) or a subclasscontrol mAb (dashedlines).
Linear fluorescence intensity is in arbitrary units.
Donor Diagnosis
Eosinophilia of donor blood
No. of eosin- Percent
ophils/mm3 eosinophils
Percent
eosinophils
on day 0 0*
Percent
CD4' eosinophils
2 3 5 7
la Hypereos 10,430 74 86 83 78 76 78 92
lb 12,260 63 90 46 81 85
2a Hypereos 13,800 46 93 11 36 41 66 54
3a Filariasis 960 17 73 48 18 19 26 20
4a Filariasis 7,300 52 71 15 47 50
4b 10,300 63 94 23 45 49
5a Idiopathic 1,870 11 67 9 11 21
6a Normal 500 5 67 13 8 14 9 18
7a Normal 500 5 90 14 13 8 18 29
8a Normal 200 2 71 10 13 9 9 6
9a Normal 200 2 80 5 36 10 12 7330
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CD4 precipitated from eosinophils comigrated with 35S-labeled PBMC CD4 on
SDS-PAGE (data not shown) with anM r identical to that previously determined
forCD4on monocytes andlymphocytes (2) . Immunoprecipitation from eosinophils
of metabolically-labeled molecules with anM r of 55,000 confirmed the identity of
the protein recognized by the anti-CD4 mAbs and also established that mature eo-
sinophils, often considered end-stage terminally differentiated cells, retain the ca-
pacity to synthesize new proteins, including CD4.
Like theCD4 molecule on human lymphocytes and monocytes, eosinophil CD4
also bindstheHIV -1 gp120 envelope glycoprotein . HIV-1 gp120 competitivelyblocked
the staining of eosinophils with mAbOKT4A, which recognizes a gp120 binding
epitope on CD4, but not the staining with OKT4, an mAb to a region ofCD4 not
involved in gp120 binding (11, 19, 20) (Fig, 3) . Eosinophils staining with anti-OKT4A
decreased from 85.4% to 26.6% after gp120 binding but anti-OKT4 staining was
unchanged from 90.8% to 89.6% with gp120 . Similar results were obtained at two
concentrations of gp120 (10 and 17 wg/ml) .
OKT4A
~,OKT4
FIGURE 3.
￿
HIV-1 gp120 binding to CD4' eosinophils. A represents
eosinophils not incubated with gpl20 andBrepresents those that were
incubated with gpl20 . Staining withmAbOKT4A, which recognizes
a gpl20 binding epitope on CD4, and with OKT4, an mAb to a re-
gion ofCD4 not involved in gp120 binding, are presented relative to
a subclass control mAb .
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FIGURE 2 .
￿
SDS-PAGE of CD4 (arrow) from cultured, ,3sS-methio-
nine-labeled eosinophils immunoprecipitated with either nonspecific
control (lane 1) or specific anti-OKT4 (lane 2) or anti-OKT4A (lane
3) mAbs . M r (x 10-3) standards are on the left .LUCEY ET AL.
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These findings demonstrate that human eosinophilic leukocytes express CD4 pro-
tein, previously recognized on leukocytes belonging to subsets of T lymphocytes or
to monocyte/macrophage lineage. The expression of CD4 by eosinophils could allow
these CD4+ eosinophils to interact with class Il MHC-bearing cells and the CD4
molecule could function as a signal-transducing ligand on these cells, as it can on
other CD4+ cells (8). Moreover, the expression on eosinophils of CD4 with its ca-
pacity to bind HIV gp120 may render the eosinophil susceptible to infection with
HIV (21). Indeed, the eosinophil's predominant localization in tissues of the gas-
trointestinal and genitourinary tracts could expose this cell in these sites to inocula
of sexually transmitted HIV. Further, increased blood and tissue eosinophilia are
usual concomitants of infections with metazoan parasites, as in donors 3 and 4 with
L. loa infections acquired in Africa. Many individuals from areas of the world, in-
cluding tropical Africa, where intestinal and extra-intestinal helminthic parasitic in-
fections are endemic, would have augmented numbers of eosinophils. The height-
ened numbers of CD4+ eosinophils in patients with chronic helminthic infections
could provide an increased population of cells susceptible to HIV infection, which
would have bearing on the epidemiology, transmission, and clinical manifestations
of these retroviral infections.
Summary
The CD4 glycoprotein, expressed on leukocytes belonging to subsets of T lym-
phocytes and to cells of monocyte/macrophage lineage, participates in the functioning
ofT cells and serves as a receptor for HIV-1 and HIV2 . Human eosinophils, a class
of granulocytic leukocytes, have been found to express CD4. With anti-CD4 mAbs
CD4 was demonstrable on eosinophils from both normal and eosinophilic donors.
Eosinophils synthesized a 55-kD CD4 polypeptide immunoprecipitable with two
anti-CD4 mAbs. Eosinophil CD4 bound HIVI gp120 as assessed by competition
for anti-OKT4A, but not anti-OKT4, mAb binding. Eosinophils, normally rich in
gastrointestinal and genitourinary tract tissues, increase in numbers in patients with
metazoan parasitic infections. In these sites and diseases, CD4 expression by eo-
sinophils may be pertinent to their immunologic functions and could make these
cells susceptible to HIV infection.
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